Griffiths S J, Bramley T A, Menzies G S, Adams D J
Department of Microbiology, University of Leeds, UK.
Mol Cell Endocrinol. 1997 Oct 31;134(1):69-76. doi: 10.1016/s0303-7207(97)00174-3.
An 18 kDa pregnancy urine protein preparation, purified to apparent electrophoretic homogeneity as judged by silver-staining of polyacrylamide gels, inhibited binding of 125I-hLH (human luteinizing hormone) to Candida albicans microsomes, reacted with monoclonal and polyclonal antibodies raised against human chorionic gonadotrophin (hCG) beta-core protein and exhibited ribonuclease (RNase) activity. Eleven of the 12 amino acids at the N-terminus of a protein in this preparation were identical to those of the N-terminus of human non-secretory ribonuclease. These results indicate co-purification of hCG beta-core with a RNase. An 18 kDa RNase was also purified from a commercial hCG preparation (Chorulon). However, no RNase activity was detected in a highly purified commercial preparation (Profasi). Three commercial RNase preparations displaced 125I-hLH from C. albicans binders at extremely low concentrations (< 0.001 microg/ml RNase) whereas only slight displacement of 125I-hLH from sheep luteal binding sites was observed with very high concentrations of the RNases (100 microg/ml RNase). The co-purification of hCG beta-core and RNase from pregnancy urine and the displacement of 125I-hLH from C. albicans binding sites by RNases may be related to the close relationship that has been identified between mammalian RNase inhibitors and the extracellular domain of gonadotrophin receptors. The presence of RNase in commercial preparations of gonadotrophins should be borne in mind during any investigations that involve impure preparations of these hormones.
一种18 kDa的妊娠尿蛋白制剂,通过聚丙烯酰胺凝胶银染判断已纯化至表观电泳均一性,它能抑制125I - hLH(人促黄体生成素)与白色念珠菌微粒体的结合,与针对人绒毛膜促性腺激素(hCG)β核心蛋白产生的单克隆和多克隆抗体发生反应,并表现出核糖核酸酶(RNase)活性。该制剂中一种蛋白质N端的12个氨基酸中有11个与人非分泌型核糖核酸酶N端的氨基酸相同。这些结果表明hCGβ核心与一种核糖核酸酶共纯化。还从一种市售hCG制剂(Chorulon)中纯化出了一种18 kDa的核糖核酸酶。然而,在一种高度纯化的市售制剂(Profasi)中未检测到核糖核酸酶活性。三种市售核糖核酸酶制剂在极低浓度(< 0.001 μg/ml核糖核酸酶)下就能从白色念珠菌结合物上取代125I - hLH,而在非常高浓度(100 μg/ml核糖核酸酶)的核糖核酸酶作用下,仅观察到从绵羊黄体结合位点对125I - hLH的轻微取代。从妊娠尿中hCGβ核心与核糖核酸酶的共纯化以及核糖核酸酶从白色念珠菌结合位点取代125I - hLH的现象可能与已确定的哺乳动物核糖核酸酶抑制剂和促性腺激素受体细胞外结构域之间的密切关系有关。在任何涉及这些激素不纯制剂的研究中,都应牢记促性腺激素市售制剂中存在核糖核酸酶这一情况。